Last updated on July 2019

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Brief description of study

Purpose of this study is to determine appropriate dosing of ABI-009 and evaluate the safety and anti-tumor activity of ABI-009 in treatment of non-muscle invasive bladder cancer

Clinical Study Identifier: NCT02009332

Find a site near you

Start Over